Shield Therapeutics

1. 27 Aug 26
   Shield assumes full control of ACCRUFeR® in the US

   Shield assumes full control of ACCRUFeR® in the US

   RNS 9744178 ↗
2. 20 Aug 26
   Half-year Results

   Interim results for the six months ended 30 June 2026

   RNS 9730759 ↗
3. 30 Jul 26
   Q2 and H1 2026 Trading Update

   Q2 revenues of $11.9M with strong growth in the commercial segment

   RNS 9694692 ↗
4. 28 Jul 26
   ACCRUFeR® Phase 3 pediatric trial published

   ACCRUFeR® Phase 3 pediatric trial published in Pediatric Drugs

   RNS 9689968 ↗
5. 18 Jun 26
   Result of AGM

   London, UK, 18 June 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency with or without anemia ("ID/IDA"), announces the voting results for each resolution set out in the Notice of Annual...

   RNS 9626189 ↗
6. 05 May 26
   Grant of Share Options

   London, UK, 05 May 2026: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 04 May 2026 it granted share awards in the form of options over ordinary shares in the capital of the...

   RNS 9550736 ↗
7. 01 May 26
   Q1 2026 Trading Update

   Group net revenues of $18M with strong year on year ACCRUFeR® net revenue growth of 54% to $9.9M

   RNS 9547945 ↗
8. 27 Apr 26
   Enrollment in Phase II Clinical Trial for ACCRUFeR

   Enrollment commenced in Phase II Clinical Trial for ACCRUFeR® (Ferric Maltol) in Japan.

   RNS 9538206 ↗
9. 09 Apr 26
   Audited results for year ended 31 December 2025

   Audited results for the year ended 31 December 2025

   RNS 9513012 ↗
10. 01 Apr 26
    Publication of Report, Reinforcing FDA Approval

    Publication of Report in Pediatric Drugs, Reinforcing FDA Approval Milestone

    RNS 9502978 ↗
11. 31 Mar 26
    EMA approves extension - to include adolescents

    European Medicines Agency approves extension of the indication to include adolescents

    RNS 9499260 ↗
12. 03 Mar 26
    Chinese NMPA Accepts MAA Submission for ACCRUFeR®

    Chinese NMPA Accepts MAA Submission for ACCRUFeR® (ferric maltol)

    RNS 9454749 ↗
13. 09 Feb 26
    FDA Grants additional Exclusivity for ACCRUFeR

    US FDA Grants additional 3 Years Exclusivity for ACCRUFeR®

    RNS 9420124 ↗
14. 30 Jan 26
    Approval for ACCRUFeR in China expected in Q1 2026

    Filing for marketing authorisation for the approval for ACCRUFeR® in China

    RNS 9394853 ↗
15. 21 Jan 26
    Q4 2025 Trading Update

    Generated positive Cash flow in Q4 2025 with Total Group Revenues of c.

    RNS 9370883 ↗
16. 22 Dec 25
    FDA approves extension for ACCRUFeR®

    US FDA approves extension of the indication for ACCRUFeR® to include

    RNS 9311326 ↗
17. 11 Dec 25
    Shield Wins Gold at Titan Branding Awards

    Shield Therapeutics Wins Gold at Titan Branding Awards for ACCRUFeR's Brand Transformation

    RNS 9289276 ↗
18. 03 Dec 25
    Amends Senior Secured Debt Financing

    Amends Senior Secured Debt Financing with improved terms

    RNS 9272076 ↗
19. 14 Nov 25
    Initiation of a Phase II Clinical Trial in Japan

    Initiation of a Phase II Clinical Trial for ACCRUFeR® (Ferric Maltol) for the

    RNS 9233224 ↗
20. 11 Nov 25
    ACCRUFeR Pediatric PK Results to be Presented

    ACCRUFeR® Pediatric Pharmacokinetic (PK) Results Will be Presented at the American Society of Hematology (ASH) Conference

    RNS 9225029 ↗
21. 07 Nov 25
    ACCRUFeR receives Authorisation by Korean Ministry

    ACCRUFeR® receives Marketing Authorisation by Korean Ministry of Food and Drug Safety (MFDS)

    RNS 9218647 ↗
22. 23 Oct 25
    Q3 2025 Trading Update

    $13.1m net revenues and an average net selling price of $237

    RNS 9188390 ↗
23. 14 Oct 25
    Grant of Share Options to Chief Executive Officer

    Grant of Share Options to Chief Executive Officer

    RNS 9170555 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.